Sinteza i biološko djelovanje novih 1-benzil i 1-benzoil 3-heterocikličkih derivata indola by ESLAM REDA EL-SAWY et al.
Indole, a potent basic pharmacodynamic nucleus, has been reported to possess a
wide variety of biological properties, viz., anti-inflammatory (1, 2), anticancer (3), anti-
depressant (4), antibacterial (5) and antifungal (6). Also, imidazole derivatives were
found to possess anti-cancer (7) and antimicrobial activities (8), as well as quinoxaline
derivatives (9, 10). Encouraged by the above observations, herein we report the synthe-
sis of some new 3-substituted-1-benzyl- and 1-benzoyl-indole derivatives and evalua-
tion of their antimicrobial and anticancer activities.
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Starting from 1-benzyl- (2a) and 1-benzoyl-3-bromoacetyl
indoles (2b) new heterocyclic, 2-thioxoimidazolidine
(4a,b), imidazolidine-2,4-dione (5a,b), pyrano(2,3-d)imida-
zole (8a,b and 9a,b), 2-substituted quinoxaline (11a,b–17a,b)
and triazolo(4,3-a)quinoxaline derivatives (18a,b and
19a,b) were synthesized and evaluated for their antimi-
crobial and anticancer activities. Antimicrobial activity
screening performed with concentrations of 0.88, 0.44
and 0.22 mg mm–2 showed that 3-(1-substituted indol-3-
-yl)quinoxalin-2(1H)ones (11a,b) and 2-(4-methyl pipera-
zin-1-yl)-3-(1-substituted indol-3-yl) quinoxalines (15a,b)
were the most active of all the tested compounds to-
wards P. aeruginosa, B. cereus and S. aureus compared to
the reference drugs cefotaxime and piperacillin, while
2-chloro-3-(1-substituted indol-3-yl)quinoxalines (12a,b)
were the most active against C. albicans compared to the
reference drug nystatin. On the other hand, 2-chloro-3-
-(1-benzyl indol-3-yl) quinoxaline 12a display potent ef-
ficacy against ovarian cancer xenografts in nude mice
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EXPERIMENTAL
Melting points were determined in open capillary tubes on an Electrothermal 9100
digital melting point apparatus (Büchi, Switzerland) and are uncorrected. Elemental
analyses were on a Perkin-Elmer 2400 analyzer (USA) and were found within ± 0.4 % of
the theoretical values (Table I). Physical and analytical data are given in Table I. IR spec-
tra were recorded on a Perkin-Elmer 1600 FTIR in KBr pellets. The 1H NMR spectra were
measured with Jeol 270 MHz (Jeol, Japan) in DMSO-d6 and chemical shifts were record-
ed in d ppm relative to TMS. Mass spectra (EI) were run at 70 eV with a Jeol-JMS-AX500
mass spectrometer. Spectral data of the synthesized compounds are listed in Table II.
1-Benzyl- (1a) and 1-benzoyl-3-acetyl (1b) indoles were prepared as reported (11).
Synthesis of 1-benzyl-3-bromoacetyl indole (2a) and 1-benzoyl-3-bromoacetyl indole (2b). General
procedure. – To a stirred and cold suspension of 1a or 1b (0.1 mol) in absolute methanol
(50 mL), bromine (16 g, 5.3 mL, 0.1 mol) in absolute methanol (10 mL) was added drop-
wise. After addition, the solvent was evaporated under vacuo. The residue was suspen-
ded in water (100 mL) and stirred for 1 h. The solid that precipitated was collected by fil-
tration and recrystallized from methanol.
Synthesis of 2-(2-(1-benzyl indol-3-yl)-2-oxoethyl amino)acetic acid (3a) and 2-(2-(1-benzoyl
indol-3-yl)-2-oxoethyl amino)acetic acid (3b). General procedure. – A suspension of 2a or 2b
(0.001 mol) and glycine (0.07 g, 0.001 mol) in potassium carbonate (5 mL, 1.1 mol L–1)
was heated at 50 °C for 10 min and then at 100 °C for 30 min. After cooling, the reaction
mixture was neutralized with diluted hydrochloric acid (1:1). The precipitate that was
formed was collected by filtration and recrystallized from aqueous dioxane.
Synthesis of 1-[(1-benzyl indol-3-yl) carbomethyl]-2-thioxoimidazolidine-4-one (4a) and 1-[(1-
-benzoyl indol-3-yl) carbomethyl]-2-thioxoimidazolidine-4-one (4b). General procedure. – A sus-
pension of 3a or 3b (0.012 mol), acetic anhydride (6.3 g, 0.067 mol), anhydrous pyridine
(15 mL) and ammonium thiocyanate (1.2 g, 0.015 mol) was heated at 110 °C for 1 h. The
volatiles were removed in vacuo and the residue was suspended in water (100 mL) and
stirred for 1 h. The solid formed was collected by filtration and recrystallized from ben-
zene-petroleum ether (60–80 °C).
Synthesis of 1-[(1-benzyl indol-3-yl) carbomethyl]imidazolidine-2,4-dione (5a) and 1-[(1-benzoyl
indol-3-yl) carbomethyl]imidazolidine-2,4-dione (5b). General procedure. – A suspension of 4a
or 4b (0.0055 mol), chloroacetic acid (10 g, 0.1 mol) and water (3 mL) was heated at 120
°C for 12 h on a sand bath. The reaction mixture was then diluted with water (50 mL) and
set aside in refrigerator at 0 °C. The solid formed was collected by filtration and recry-
stallized from benzene-petroleum ether (60–80 °C).
Synthesis of 5-(4-fluorobenzylidine)-1-(1-benzyl indol-3-yl)-2-thioxoimidazolidine-4-one (6a), 5-
-(4-fluorobenzylidine)-1-(1-benzoyl indol-3-yl)-2-thioxo-imidazolidine-4-one (6b), 5-(4-fluoroben-
zylidine)-1-(1-benzyl indol-3-yl)imidazolidine-2,4-dione (7a) and 5-(4-fluorobenzylidine)-1-(1-
-benzoyl indol-3-yl)imidazolidine-2,4-dione (7b). General procedure. – To a solution of 4a,b or
5a,b (0.001 mol) in absolute ethanol (10 mL) containing 3 drops of triethylamine, p-flu-
oro-benzaldehyde (0.11 g, 0.001 mol) was added. The reaction mixture was refluxed for 3 h.
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2a C17H14BrNO (328.20) 90–92 23 62.21/62.00 4.30/4.08 4.27/4.10
2b C17H12BrNO2 (342.19) 109–111 30 59.67/59.55 3.53/3.42 4.09/4.00
3a C19H18N2O3 (322.36) 366–368 30 70.79/70.60 5.63/5.39 8.69/8.56
3b C19H16N2O4 (336.34) 96–98 61 67.85/67.77 4.79/4.57 8.33/8.21
4a C20H17N3O2S (363.43) 280–282 61 66.10/66.00 4.71/4.55 11.56/11.44
4b C20H15N3O3S (377.42) 150–152 81 63.65/63.46 4.01/3.89 11.13/11.00
5a C20H17N3O3 (347.37) 210–212 86 69.16/69.00 4.93/4.70 12.10/12.22
5b C20H15N3O4 (361.35) 255–257 60 66.48/66.27 4.18/4.00 11.63/11.51
6a C27H20FN3O2S (469.53) 157–159 42 69.07/69.00 4.29/4.06 8.95/8.94
6b C27H18FN3O3S (483.51) 112–114 64 67.07/67.20 3.75/3.53 8.69/8.70
7a C27H20FN3O3 (453.46) 252–254 30 71.51/71.40 4.45/4.22 9.27/9.30
7b C27H18FN3O4 (467.45) 245–247 58 69.37/69.27 3.88/3.67 8.99/9.01
8a C30H22FN5O2S (535.59) 189–191 67 67.28/67.41 4.14/3.81 13.08/13.01
8b C30H20FN5O3S (549.57) 161–163 74 65.56/65.67 3.67/3.09 12.74/12.66
9a C30H22FN5O3 (519.17) 142–144 70 69.36/69.47 4.27/3.67 13.48/13.45
9b C30H20FN5O4 (533.51) 282–284 67 67.54/67.66 3.78/3.58 13.13/13.00
11b C23H15N3O2 (365.12) 212–214 60 75.60/75.49 4.10/4.24 11.50/11.45
12a C23H16ClN3 (369.85) 103–105 65 74.69/74.71 4.36/4.13 11.37/11.29
12b C23H14ClN3O (383.83) 119–121 61 71.97/72.00 3.68/3.49 10.95/11.01
13a C28H26N4 (41853) 176–178 53 80.35/80.40 6.26/6.01 13.39/13.25
13b C28H24N4O (432.53) 310–312 60 77.75/77.60 5.59/5.45 12.95/13.00
14a C27H24N4O (420.51) 187–189 55 77.12/77.00 5.75/5.59 13.32/13.20
14b C27H22N4O2 (434.49) 232–234 60 74.64/74.50 5.10/5.20 12.89/12.85
15a C28H27N5 (433.55) 124–126 50 77.57/77.40 6.28/6.10 16.15/6.10
15b C28H25N5O (447.53) 210–212 60 75.51/75.39 5.62/5.45 15.65/15.55
16a C23H19N5 (365.43) 101–103 50 75.59/75.42 5.24/5.00 19.16/19.20
16b C23H17N5O (379.41) 178–180 60 72.82/72.91 4.52/4.31 18.47/18.26
17a C23H16N6 (376.41) 112–114 48 73.39/73.21 4.28/4.30 22.33/22.15
17b C23H14N6O (390.40) 176–178 60 70.76/70.55 3.61/3.48 21.53/21.40
18a C24H17N5 (375.43) 142–144 47 76.78/76.61 4.56/4.51 18.65/18.30
18b C24H15N5O (383.41) 91–93 58 74.02/73.99 3.88/4.01 17.98/18.01
19a C25H19N5 (389.45) 198–200 55 77.10/76.98 4.92/4.85 17.98/18.00
19b C25H17N5O (403.44) 223–225 60 74.43/74.20 4.25/4.20 17.36/17.65
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8.11 (s, 1H, H-2 indole), 7.01–7.67
(m, 9H, Ar-H), 5.56 (s, 2H, CH2-N),
5.03 (s, 2H, CH2-CO)
327 (M+, 12), 329 (M++2,
10), 237 (25), 143 (25), 130





7.13–8.27 (m, 10H, Ar-H),
5.51 (s, 2H, CH2-CO)
341 (M+, 7), 343 (M++2, 5),






12.51 (s, 1H, OH), 9.92 (s, 1H, NH),
8.21 (s, 1H, H-2 indole), 7.07–7.90
(m, 9H, Ar-H), 5.56 (s, 2H, CH2-N),






12.61 (s, 1H, OH), 11.21 (s, 1H,
NH), 8.12 (s, 1H, H-2 indole),
7.03–7.67 (m, 9H, Ar-H), 4.11 and






11.55 (s, 1H, NH), 8.12 (s, 1H, H-2
indole), 7.03–7.87 (m, 9H, Ar-H),
5.61 (s, 2H, CH2-N), 4.12 and 4.01
(2s, 4H, 2CH2)
363 (M+, 10), 249 (86), 234






11.62 (s, 1H, NH), 8.21 (s, 1H, H-2
indole), 7.01–7.67 (m, 9H, Ar-H),
4.03 and 4.12 (2s, 4H, 2CH2)
377 (M+, 58), 321 (20), 234





12.51 (s, 1H, NH), 8.12 (s, 1H, H-2
indole), 7.01–7.87 (m, 9H, Ar-H),
5.56 (s, 2H, CH2-N), 4.12 and 4.10
(2s, 4H, 2CH2)
347 (M+, 30), 249 (71), 207





11.91 (s, 1H, NH), 8.12 (s, 1H, H-2
indole), 7.01–7.64 (m, 9H, Ar-H),






11.25 (s, 1H, NH), 8.12 (s, 1H, H-2
indole), 7.01–7.60 (m, 13H, Ar-H),
6.54 (s, 1H, CH=C), 5.65 (s, 2H,






10.5 (s, 1H, NH), 8.0 (s, 1H, H-2
indole), 7.0–7.68 (m, 13H, Ar-H),
6.56 (s, 1H, CH=C), 4.12 (s, 2H,
CH2)
483 (M+, 20), 427 (50), 263






10.17 (s, 1H, NH), 8.12 (s, 1H, H-2
indole), 7.07–7.68 (m, 13H, Ar-H),
6.65 (s, 1H, CH=C), 5.36 (s, 2H,
CH2-N), 4.11 (s, 2H, CH2)
7b
3210 (NH), 1710 and
1735 (C=O), 1635
and 1601 (C=C)
10.17 (s, 1H, NH), 8.21 (s, 1H, H-2
indole), 7.07–7.68 (m, 13H, Ar-H),
6.90 (s, 1H CH=C), 4.20 (s, 2H, CH2)
467 (M+, 30), 355 (16), 264
(20), 119 (71), 105 (100)
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8.12 (s, 1H, H-2 indole), 7.18–7.67
(m, 13H, Ar-H), 5.76 (s, 2H, NH2),









8.21 (s, 1H, H-2 indole), 7.01–7.68
(m, 13H, Ar-H), 5.80 (s, 2H, NH2),
4.12 (s, 2H, CH2)
547 (M+, 61), 502 (30), 264







8.12 (s, 1H, H-2 indole), 7.16–7.76
(m, 13H, Ar-H), 5.90 (s, 2H, NH2),








8.12 (s, 1H, H-2 indole), 7.09–7.78
(m, 13H, Ar-H), 6.17 (s, 2H, NH2),
4.12 (s, 2H, CH2)
531 (M+, 30), 503 (50), 396





9.88 (s, 1H, NH), 7.08–7.97 (m, 14H,
Ar-H)
365 (M+, 20), 313 (100), 235




7.09–7.87 (m, 14H, Ar-H), 5.61 (s,
2H, CH2-N)
369 (M+, 70), 371 (M++2,
15), 335 (23), 306 (10), 206





7.99 (s, 1H, H-2 indole), 7.91–7.67
(m, 13H, Ar-H)
383 (M+, 37), 385 (M++2,





418 (M+, 18), 325 (40), 269





8.12 (s, 1H, H-2 indole), 7.07–7.76






420 (M+, 18), 404 (2), 350












433 (M+, 28), 348 (50), 232





8.12 (s, 1H, H-2 indole), 7.01–7.68
(m, 13H, Ar-H), 3.12 (s, 3H, CH3-N),





8.9 (s, 1H, NH), 7.1–8.1 (m, 14H,
Ar-H), 5.5 (s, 2H, CH2-N), 4.1 (s,
2H, NH2)
365 (M+, 3.35), 315 (100),
274 (2), 243 (4), 208 (37), 91
(98)
After evaporation of all solvent under vacuo, the residue was suspended in water (20
mL) and the solid formed was collected by filtration and recrystallized from aqueous
ethanol to give 6a,b and 7a,b, respectively.
Synthesis of 5-amino-7-(4-fluorophenyl)1,2,3,3a-tetrahydro-1-[1-benzyl indol-3-yl]carbomethyl)-
-2-thioxopyrano(2,3-d)imidazole-6-carbonitrile (8a), 5-amino-7-(4-fluorophenyl)1,2,3,3a-tetra-
hydro-1-[1-benzoyl indol-3-yl] carbomethyl)-2-thioxopyrano(2,3-d)imidazole-6-carbonitrile (8b),
5-amino-7-(4-fluorophenyl)1,2,3,3a-tetrahydro-2-oxo-1-[1-benzyl indol-3-yl] carbomethyl) pyra-
no(2,3-d)imidazole-6-carbonitrile (9a) and 5-amino-7-(4-fluorophenyl)1,2,3,3a-tetrahydro-2-oxo-
-1-[1-benzoyl indol-3-yl] carbomethyl)pyrano(2,3-d)imidazole-6-carbonitrile (9b). Method A. – A
mixture of 4a,b or 5a,b (0.0005 mol) and p-fluorobenzylidene malononitrile (0.086 g,
0.0005 mol) in absolute ethanol (10 mL) containing triethylamine (0.5 mL) was refluxed
for 2 h. The solid that formed was collected by filtration and recrystallized from dioxane.
Method B. – A mixture of 6a,b or 7a,b (0.001 mol) and malononitrile (0.066 g, 0.001
mol) in absolute ethanol (10 mL) containing triethylamine (0.5 mL) was refluxed for 3 h.
The solid that formed was collected by filtration and recrystallized from dioxane.
Synthesis of 3-(1-benzyl indol-3-yl)quinoxalin-2(1H)one (11a) and 3-(1-benzoyl indol-3-yl)qui-
noxalin-2(1H)one (11b). General procedure. – To a solution of o-phenylenediamine (1.1 g,
0.01 mol) in absolute ethanol (20 mL) 10a or 10b (0.01 mol) was added. The reaction mix-
ture was refluxed on a water bath for 1 h. The solvent was then evaporated to dryness
under vacuo and the resulting residue was triturated with water (30 mL). The solid for-
med was collected by filtration, air-dried and recrystallized from chloroform.
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379 (M+, 0.1), 335 (60), 323






7.0–8.1 (m, 14H, Ar-H), 5.6 (s, 2H,
CH2-N)
376 (M+, 10), 312 (100), 235






390 (M+, 3), 335 (81), 244





8.2 (s, 1H, CH-triazole), 8.01 (s, 1H,
H-2 indole), 7.1–7.98 (m, 13H,
Ar-H), 5.56 (s, 2H, CH2-N)
375 (M+, 3), 298 (100), 245






389 (M+, 1), 335 (40), 325





8.01 (s, 1H, H-2 indole), 7.1–7.67 (m,
13H, Ar-H), 5.56 (s, 2H, CH2-N), 2.1
(s, 3H, CH3)
389 (M+, 15), 314 (87), 296






403 (M+, 2), 335 (51), 244
(10), 204 (50), 91 (100), 65
(10)
Synthesis of 2-chloro-3-(1-benzyl indol-3-yl)quinoxaline (12a) and 2-chloro-3-(1-benzoyl indol-
-3-yl)quinoxaline (12b). General procedure. – A solution of 11a or 11b (0.01 mol) in phos-
phorus oxychloride (20 mL) was heated on a sand bath at 130 °C for 1 h. After cooling,
the reaction mixture was poured onto ice-water under stirring and the solid that formed
was collected by filtration, air-dried and recrystallized from chloroform.
Synthesis of 2-(piperidin-1-yl)-3-(1-benzyl indol-3-yl)quinoxaline (13a), 2-(piperidin-1-yl)-
-3-(1-benzoyl indol-3-yl)quinoxaline (13b), 2-morpholino-3-(1-benzyl indol-3-yl)quinoxaline
(14a), 2-morpholino-3-(1-benzoyl indol-3-yl)quinoxaline (14b), 2-(4-methylpiperazin-1-yl)-3-(1-
-benzyl indol-3-yl)quinoxaline (15a) and 2-(4-methylpiperazin-1-yl)-3-(1-benzoyl indol-3-yl)qui-
noxaline (15b). General procedure. – Compound 12a or 12b (0.01 mol) was fused with an
appropriate aliphatic cyclic amine (0.01 mol) at 150 °C on a sand bath for 3 h. After cool-
ing and addition of water (20 mL), the solid formed was collected by filtration, air-dried
and recrystallized from chloroform.
Synthesis of 1-(2-(1-benzyl indol-3-yl)quioxalin-3-yl)hydrazine (16a) and 1-(2-(1-benzoyl
indol-3-yl)quioxalin-3-yl)hydrazine (16b). General procedure. – To a solution of 12a or 12b
(0.01 mol) in absolute ethanol (50 mL), hydrazine hydrate (2.5 mL, 99 %, 0.05 mol) was
added and the reaction mixture was refluxed for 3 h. The solid that formed after cooling
in refrigerator was collected by filtration and recrystallized from ethanol.
Synthesis of 2-azido-3-(1-benzyl indol-3-yl)quinoxaline (17a) and 2-azido-3-(1-benzoyl
indol-3-yl)quinoxaline (17b). General procedure. – A cold solution (0–5 °C) of sodium nitrite
(1 g, 0.144 mol) in water (15 mL) was added gradually within 15 min to a cold solution
of 16a or 16b (0.01 mol) in concentrated hydrochloric acid (5 mL). After addition, the re-
action mixture was set aside at room temperature for 1 h. The solid that formed was col-
lected by filtration, air dried and recrystallized from chloroform.
Synthesis of 4-(1-benzyl indol-3-yl)-(1,2,4)-triazolo(4,3-a)quinoxaline (18a), 4-(1-benzoyl
indol-3-yl)-(1,2,4)-triazolo(4,3-a)quinoxaline (18b), 1-methyl-4-(1-benzyl indol-3-yl)-(1,2,4)-tria-
zolo(4,3-a)quinoxaline (19a) and 1-methyl-4-(1-benzoyl indol-3-yl)-(1,2,4)-triazolo(4,3-a)quin-
oxaline (19b). General procedure. – Compound 16a or 16b (0.01 mol) was treated with for-
mic acid (25 mL) or acetic acid (25 mL) and allowed to stand at room temperature for 24 h
and then refluxed for 4 h. After cooling, the reaction mixture was poured onto crushed ice
and the suspension formed was filtered off, air-dried and recrystallized from chloroform.
Biological assays
Antimicrobial evaluation. – Antimicrobial activity of the synthesized compounds was
determined in vitro using the disc diffusion method (12) against pathogenic microorga-
nisms: Escherichia coli, Pseudomonas aeruginosa (Gram-negative bacteria), Staphylococcus
aureus, Bacillus cereus (Gram-positive bacteria) and one strain of fungi (Candida albicans).
They were isolated from clinical samples and identified to the species level according to
API 20E system (Analytab Products, Inc., USA) (bioMerieux, Australia). Antimicrobial
activities of the tested compounds were estimated by placing presterilized filter paper
discs (6 mm in diameter) impregnated with 25, 50 and 100 mg per disc in nutrient and
MacConky agar media for bacteria and on Sabouraud dextrose agar for fungus. Dime-
thyl formamide (DMF) which showed no inhibition zone was used as a solvent for im-
pregnation. The inhibition zones (IZ) of the tested compounds were measured after
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24–48 h incubation at 37 °C for bacteria and after 5 days incubation at 28 °C for fungi.
Cefotaxime (Hoechst-Roussel Pharmaceuticals, Germany, 30 mg per disc) and piperaci-
llin (Bristol-Myers Squibb, Egypt, 100 mg per disc) were used as reference drugs for bac-
teria, while nystatin (Bristol-Myers Squibb, Egypt, 1.2 mg per disc) was used as reference
drug for fungi.
Anti-cancer evaluation. In vitro studies. – Human ovarian cancer cell lines (OVCAR3
and BG-1) were obtained from the American Type Culture Collection, Rockville, USA).
OVCAR3 cells were propagated in sterile growth medium RPMI-1640* (Sigma-Aldrich,
Germany) supplemented with 10 % fetal calf serum (Life Technologies, USA) and 1 %
antibiotic mixture penicillin G sodium and streptomycin sulphate, Gibco Germany). BG-1
cells were propagated in DMEM/F-12** medium supplemented with 10 % fetal calf se-
rum. Cells were incubated at 5 % CO2 and at 37 °C.
Cytotoxicity test (MTT). – Cytotoxicity of the synthesized compounds was determi-
ned using the MTT [3-(4,5-dimethylthiazoyl-2-yl)2,5-diphenyltetrazolium bromide] as-
say according to Mosmann (13). Subconfluent cells (logarithmically growing cells) were
trypsinized and collected.
Cells were seeded in 96-well micro-plates (3 ´ 103 cells per well) in 100 mL RPMI-
-1640 culture medium and incubated at 37 °C and 5 % CO2 overnight. After overnight
incubation, the cells were treated with the synthesized compounds dissolved in 10 mL
DMSO per well and then incubated for further 24 hours. The medium was discarded
and the cells were washed with sterile PBS; then 100 mL of the MTT (0.5 mg mL–1) solu-
tion were added to each well and cells were incubated for 4 h. The developed purple
crystals were dissolved in 100 mL DMSO and absorbance was measured at 570 nm (ELISA
reader, Biorad, USA).
Growth suppression of ovarian cancer xenografts in nude mice. In vivo studies. – Female
Swiss albino mice weighing 25–30 g obtained from Harlan Sprague Dawley, (USA) were
housed at a constant temperature (24 ± 2 °C) with alternating 12 h light and dark cycles
and fed standard laboratory food and water ad libitum. Statistical analysis was prefor-
med using the SPSS version 11.0. Data were expressed as percent of control of mean ±
SD by one-way analysis of variance (ANOVA) followed by the LSD-test. All procedures
involving animals were carried out in accordance with the guidelines for the care and
use of laboratory animals and were approved by the Ethics Committee of the National
Research Centre Cairo, Egypt. For inoculation into nude mice, OVCAR3 cells were wa-
shed with PBS, trypsinzed, resuspended in RPMI-1640 containing fetal calf serum, and
pooled. After centrifugation, cells were resuspended in matrigel (BD Biosciences Disco-
very Labware, USA)-RPMI-1640 (1:1) at a concentration of 5 ´ 106 cells per 0.1 mL of ma-
trigel. The mixture (0.1 mL) was injected subcutaneously into female athymic nude mice
on the dorsal surface. Treatment began when the tumor reached a volume of 150 mm3
on average, which took ~4 weeks. Mice were randomized and treated orally by the tes-
ted compounds daily. Tumor volumes and body masses were monitored every 5 days
over the course of treatment. Mice were sacrificed after 30 days of treatment (14).
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* Roswall Park Memorial Institute
** Dulbecco’s Modified Eagle Medium: nutrient mixture F-12
RESULTS AND DISCUSSION
Chemistry
A similar method as that described by Bodendorf and Walk (15) for the preparation
of 3-bromoacetyl indole was used to prepare the new starting compounds, 1-benzyl- (2a)
and 1-benzoyl-3-bromoacetyl (2b) indoles. Mass spectra of 2a and 2b showed molecular
ion peaks at m/z % = 327/329 (M+/M++2, 12/10) and 341/343 (M+/M++2, 7/5), respec-
tively (Table II).
Reaction of 2a,b with glycine in the presence of saturated potassium carbonate solu-
tion led to the formation of 2-(2-(1-benzyl indol-3yl)-2-oxoethyl amino)acetic acid (3a)
and 2-(2-(1-benzoyl indol-3yl)-2-oxoethyl amino)acetic acid (3b) (Scheme 1). Heterocy-
clization of the latter compounds via their reactions with ammonium thiocyanate in acetic
anhydride and in the presence of anhydrous pyridine using the method of Okuda et al.
(16) gave 2-thioxoimidazolidine-4-one derivatives (4a,b) (Scheme 1). IR spectra of 4a,b
showed absorption bands at 1240 cm–1 for C–S besides the carboxamide group peaks at
1675 and 1686 cm–1. In addition, 1H NMR spectrum of 4a revealed singlet signals at 4.01
and 4.12 ppm for CH2 of the imidazolyl and carbomethyl groups, respectively, besides
CH2 of benzyl at 5.61 ppm (Table II).
Acid hydrolysis of compounds 4a,b using aqueous monochloroacetic acid yielded
the corresponding imidazolidine-2,4-dione derivatives (5a,b) (Scheme 1). IR spectra of
5a,b showed no absorption bands for C=S but showed an absorption band at 1705–1715
cm–1 for (C=O) groups.
Base catalyzed reaction of 4a,b and 5a,b with p-fluorobenzaldehyde led to the for-
mation of the corresponding arylidene derivatives 6a,b and 7a,b, respectively (Scheme
1). Similarly to Mandour and Kassem’s procedure (17), condensation of the latter com-
pounds with malononitrile under reflux and in the presence of a base led to the forma-
tion of condensed systems of pyrano(2,3-d)imidazole derivatives 8a,b and 9a,b, respec-
tively (Scheme 1). The latter compounds could also be obtained by the condensation of
4a,b and 5a,b with p-fluorobenzylidene malononitrile in the presence of a base (Scheme
1). The products obtained by the two methods are identical in all aspects and were com-
pared by TLC and melting points, which showed no differences. IR spectra of compo-
unds 8a,b and 9a,b showed characteristic absorption bands at 2220–2223 cm–1 for CN
and at 3220–3330 cm–1 for NH2. The 1H NMR spectra of 8a,b and 9a,b showed the ab-
sence of CH=C protons of the parent compounds 6a,b and 7a,b but revealed singlet sig-
nals, 2H, of NH2 at 5.76, 5.80, 5.90 and 6.1 ppm, respectively, besides other signals which
showed similar shifts to that of the protons of the starting compounds (Table II).
Oxidation of compounds 2a,b with selenium dioxide in absolute methanol under
reflux afforded methyl 2-(1-benzyl indol-3-yl)-2-oxoacetate (10a) and methyl 2-(1-benzoyl
indol-3-yl)-2-oxoacetate (10b) (18, 19) (Scheme 2). Heterocyclization of compounds 10a,b
was afforded by their reactions with o-phenylenediamine to give quinoxaline-2(1H)-one
derivatives 11a,b; compound 11a was previously reported (20).
Compounds 11a,b, upon heating with excess of phosphorus oxychloride, afforded
the corresponding 2-chloroquinoxaline derivatives 12a,b (Scheme 2). Reactivity of com-
pounds 12a and 12b as chlorocompounds was tested via their reactions with different
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secondary amines, namely piperidine, morpholine and N-methylpiperazine and gave
2-substituted quinoxaline derivatives 13a,b-15a,b, respectively (Scheme 2).
Reaction of 12a,b with hydrazine hydrate in refluxed ethanol yielded the correspon-
ding hydrazino derivatives 16a,b (Scheme 2). Diazotization of 16a,b using sodium ni-
trite and concentrated hydrochloric acid led to the formation of the azido derivatives
17a and 17b (Scheme 2).
On the other hand, the resulting hydrazine compounds 16a,b were further conver-
ted to 1,2,4-triazolo(3,4-a)quinoxaline derivatives 18a,b and 19a,b upon refluxing in for-
mic acid and acetic acid, respectively (Scheme 2). Structures of the new compounds were
confirmed on the basis of elemental analyses (Table I) as well as spectral data, IR, 1H
NMR, and MS (Table II).
Antimicrobial activity
All the synthesized compounds were tested for their antimicrobial activity against
pathogenic microorganisms E. coli, P. aeruginosa (Gram-negative bacteria), S. aureus, B.
cereus (Gram-positive bacteria) and one strain of fungi (C. albicans) at concentrations of
0.88, 0.44 and 0.22 mg mm–2 (Table III). Compounds 15a,b were the most active of all the
tested compounds, with inhibition zones bigger or comparable to that obtained by refer-
ence drugs against P. aeruginosa, S. aureus and B. cereus; the same applies to 11a,b against
E. coli and P. aeruginosa. On the other hand, compounds 12a and 12b were found to be
most active of all the tested compounds with inhibition zone of 32 mm against C. albi-
cans compared to the reference drug nystatin (40 mm) at 1.2 mg per disc. The rest of the
tested compounds were non-active against all microorganisms.
Anticancer activity
All the synthesized compounds were initially screened for in vitro anticancer activ-
ity at a concentration of 10–7 mol L–1 against two human cancer cell lines, OVCAR3 and
BG-1, compared to vitamin D [1,25(OH)2D3] (10–7 mol L–1) using the MTT assay (13).
The growth inhibition action of the tested compounds was reported after 24 and 48 h for
each cell line (Table IV). Compounds 18a, 12a and 12b were found to be the most cy-
totoxic, with growth inhibition of 98.5 ± 1.2, 97 ± 0.6 and 96.14 ± 0.5 %, respectively, after
treatment for 24 h and 99.9 ± 1.5, 98.6 ± 0.6 and 97.6 ± 0.6, respectively, after treatment
for 48 h compared to vitamin D (43.9 ± 7.8 and 59.8 ± 5.3 %) against OVCAR3. Also,
compounds 18a, 12a and 12b were most cytotoxic against BG-1, with inhibition growth
of 98.9 ± 1.1, 98.0 ± 0.8 and 97.7 ± 0.7 %, respectively, after treatment for 24 h and 99.8 ±
1.3, 98.9 ± 0.8 and 98.0 ± 0.5 %, respectively, after treatment for 48 h compared to vitamin
D (62.4 ± 17.7 and 71.1 ± 14.2 %), respectively.
The most cytotoxic of all the tested compounds (4a,b, 5a,b, 12a,b, 13a,b, 14a, 15a,
17a, 18a,b and 19a,b) were next evaluated for in vivo growth suppression of ovarian cancer
xenografts in nude mice. OVCAR3 cell was injected subcutaneously to a size of about 150
mm3. Subsequently, daily drug administration of 1 mmol per day per gram body mass was
conducted for five days and mice were scarificed after 30 days of treatment (Table V).
Data expressed as percent of tumor growth suppression compared to control were calcu-
lated. 2-Chloro-3-(1-benzyl indol-3-yl) quinoxaline (12a) showed potent efficacy, with tu-
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E. coli P. aeruginosa S. aureus B. cereus C. albicans
Concentration (mg mm–2)
0.88 0.44 0.22 0.88 0.44 0.22 0.88 0.44 0.22 0.88 0.44 0.22 0.88 0.44 0.22
4a 18 14 10 17 12 8 14 9 5 14 9 – 26 16 10
4b 16 12 10 17 12 8 14 9 5 14 9 – 24 16 10
5a 14 9 – 14 10 7 14 9 5 14 9 – 20 14 10
5b 14 9 – 14 10 7 14 9 5 14 9 – 20 14 10
6a 15 10 8 14 10 7 14 9 5 14 9 – 28 16 10
6b 15 10 8 14 10 7 14 9 5 14 9 – 28 16 10
7a 14 9 – 14 10 7 12 8 5 12 8 – 26 16 10
7b 14 9 5 14 10 7 12 8 5 12 8 – 26 16 10
8a 12 8 5 12 8 – 11 7 – 11 8 – 26 16 10
8b 12 8 5 12 8 – 11 7 – 11 8 – 26 16 10
9a 11 8 5 11 8 – 11 7 – 11 8 – 26 16 10
9b 11 8 5 11 8 – 11 7 – 11 8 – 26 16 10
11a 22 19 17 21 20 15 21 14 14 21 19 15 – – –
11b 26 22 20 21 20 15 21 14 14 12 19 15 – – –
12a 17 14 10 18 14 10 18 14 10 17 14 10 32 25 12
12b 17 14 10 18 14 10 17 14 10 17 14 10 32 25 12
13a 11 7 – 11 7 – 11 7 – 11 7 – 22 15 10
13b 11 7 – 11 7 – 11 7 – 11 7 – 22 15 10
14a 11 7 – 11 7 – 11 7 – 11 7 – 22 15 10
14b 11 7 – 11 7 – 11 7 – 11 7 – 22 15 10
15a 24 20 15 25 20 17 24 20 17 28 20 17 – – –
15b 24 20 15 25 20 17 24 20 17 28 20 17 – – –
16a 11 7 – 11 7 – 11 7 – 11 7 – 11 7 –
16b 11 7 – 11 7 – 11 7 – 11 7 – 11 7 –
17a 11 7 – 11 7 – 11 7 – 11 7 – 11 7 –
17b 11 7 – 11 7 – 11 7 – 11 7 – 11 7 –
18a 11 7 – 11 7 – 11 7 – 11 7 – 11 7 –
18b 11 7 – 11 7 – 11 7 – 11 7 – 11 7 –
19a 11 7 – 11 7 – 11 7 – 11 7 – 11 7 –
19b 11 7 – 11 7 – 11 7 – 11 7 – 11 7 –
Cefotaxime
(0.27 mg mm–2)
32 22 17 22 18 12 31 26 17 26 20 14 – – –
Piperacillin – – – 20 15 10 27 18 10 20 15 10 – – –
Nystatin
(0.01 mg mm–2)
– – – – – – – – – – – – 40
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Table IV. In vitro cytotoxic activity of synthesized compoundsa
Compd.
No.
OVCAR3 cell BG-1 cell
Growth inhibition (%) after treatment for
24 hb 48 hb 24 hb 48 hb
Vitamin D 43.9 59.8 62.4 71.1
4a 91.3 93.3 91.3 94.2
4b 80.1 82.1 85.4 86.6
5a 90.2 92.7 90.3 92.5
5b 87.9 90.4 88.5 90.8
6a 28.6 35.6 48.6 56.5
6b 19.6 24.8 29.7 35.7
7a 40.9 58.9 60.8 68.7
7b 38.7 49.5 54.8 59.4
8a 45.7 59.8 62.6 63.6
8b 22.7 28.7 40.9 44.8
9a 21.0 27.6 38.7 41.7
9b 39.1 53.3 58.6 65.9
11a 29.6 38.9 50.0 57.3
11b 42.8 59.1 61.3 71.2
12a 97.5 98.6 98.0 98.9
12b 96.1 97.6 97.7 98.0
13a 55.4 65.7 67.4 70.3
13b 48.6 59.9 62.7 64.5
14a 49.2 61.6 65.4 68.8
14b 23.7 30.9 41.6 48.7
15a 65.5 69.1 70.6 72.3
15b 26.5 34.5 46.5 53.6
16a 20.6 26.7 31.6 38.2
16b 25.6 32.7 44.4 51.9
17a 70.9 72.1 74.1 77.8
17b 68.7 70.6 72.1 75.6
18a 98.5 99.9 98.9 99.8
18b 75.1 77.1 80.3 82.6
19a 94.4 96.6 94.5 96.1
19b 74.6 76.2 77.8 79.6
Negative control: 10 mL DMSO per well added to control cells.
a c = 10–7 mol L–1.
b Mean value of duplicate analyses.
mor growth suppression 100.0 ± 0.3 % after 25 days, whereas vitamin D showed tumor
growth suppression of 98.6 ± 5.4 % after 25 days.
CONCLUSIONS
Described herein are the synthesis, antimicrobial and anticancer activities of some
new 1-benzyl- and 1-benzoyl-3-heterocyclic indole derivatives. The results show that
compounds 3-(1-substituted indol-3-yl)quinoxalin-2(1H)ones (11a,b) and 2-(4-methyl pi-
perazin-1-yl)-3-(1-substituted indol-3-yl) quinoxalines (15a,b) were most active against
P. aeruginosa, B. cereus and S. aureus, while 2-chloro-3-(1-substituted indol-3-yl)quinoxali-
nes (12a,b) were most active against C. albicans. On the other hand, 2-chloro-3-(1-benzyl
indol-3-yl) quinoxaline (12a) displays potent efficacy of ovarain cancer xenografts in nu-
de mice with complete tumor growth suppression. Finally, this SAR study has indicated
that the conjugated indole-quinoxaline is vital for the antimicrobial activity and poten-
tial anti-cancer efficacy.
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Table V. In vivo growth inhibition of xenografts in nude mice treated with tested compoundsa
Compd.
No.
Tumor growth suppression (mean ± SD) (%)
5 days 10 days 15 days 20 days 25 days 30 days
Vitamin D 23.5 ± 1.2 55.5 ± 5.4 77.7 ± 4.4 80.1 ± 4.2 98.6 ± 5.4 100.0 ± 1.2
4a 30.8 ± 0.7 58.7 ± 0.6 65.9 ± 0.8c 77.8 ± 0.7c 89.0 ± 0.8c 90.6 ± 0.7c
4b 22.0 ± 0.2 41.9 ± 0.8 57.0 ± 1.2 64.9 ± 0.8c 67.1 ± 1.5c 79.0 ± 1.5c
5a 24.0 ± 0.8 46.5 ± 0.8 59.0 ± 0.9 67.1 ± 0.7c 73.2 ± 0.7c 81.2 ± 0.6c
5b 22.3 ± 0.5 43.1 ± 0.8 58.2 ± 0.8 66.2 ± 0.7c 70.2 ± 0.7c 80.0 ± 1.2c
12a 41.5 ± 0.6 70.8 ± 0.7c 88.2 ± 0.8c 98.6 ± 1.5c 100.0 ± 0.3c –
12b 40.0 ± 0.8 69.8 ± 0.8c 88.2 ± 0.6c 90.5 ± 0.3c 99.5 ± 1.3c 100.0 ± 0.1c
13a 12.0 ± 0.2 30.7 ± 0.7 46.0 ± 0.8 51.3 ± 0.7 59.5 ± 0.7 69.7 ± 0.7c
14a 10.0 ± 0.9 25.3 ± 0.7 39.7 ± 0.8 51.3 ± 0.7 59.5 ± 0.7c 69.7 ± 0.7c
15a 15.0 ± 0.8 33.1 ± 0.8 46.3 ± 0.9 51.9 ± 0.9 60.7 ± 0.8c 73.1 ± 0.7c
17a 20.8 ± 0.6 34.2 ± 0.6 47.1 ± 0.8 55.3 ± 0.7 60.9 ± 0.8c 75.0 ± 0.7c
17b 20.0 ± 0.8 35.1 ± 0.8 51.5 ± 0.8 55.6 ± 0.8 60.1 ± 0.8c 75.8 ± 0.6c
18a 39.7 ± 0.9 66.8 ± 0.8c 71.8 ± 0.2c 81.0 ± 0.7c 95.7 ± 0.1c 96.9 ± 0.6c
18b 21.8 ± 0.7 39.5 ± 0.6 54.8 ± 0.5 60.1 ± 0.7 65.2 ± 0.7c 78.0 ± 0.8c
19a 33.8 ± 0.6 55.7 ± 0.6 67.9 ± 0.8c 79.8 ± 0.7c 91.9 ± 0.8c 95.0 ± 1.5c
19b 21.1 ± 0.1 39.2 ± 0.6 56.1 ± 1.2 59.1 ± 0.9 61.9 ± 0.1c 77.1 ± 0.8c
Negative controls: mice injected with 0.1 mL saline.
a 1 mmol of the tested compounds per day per gram body mass.
b Mean ± SD, n = 10.
c Significantly different from control, p < 0.05.
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S A @ E T A K
Sinteza i biolo{ko djelovanje novih 1-benzil i 1-benzoil
3-heterocikli~kih derivata indola
ESLAM REDA EL-SAWY, FATMA A. BASSYOUNI, SHERIFA H. ABU-BAKR, HANAA M. RADY i MOHAMED M. ABDLLA
U radu je opisana sinteza, antimikrobno i antitumorsko djelovanje heterocikli~kih
derivata indola. Polaze}i iz 1-benzil- i 1-benzoil-3-bromacetil indola (2a i 2b) sintetizirani
su novi heterocikli~ki spojevi 2-tioksoimidazolidini (4a,b), imidazolidin-2,4-dioni (5a,b),
pirano(2,3-d)imidazoli (8a,b i 9a,b), 2-supstituirani kinoksalini (11a,b-17a,b) i triazo-
lo(4,3-a)kinoksalini (18a,b i 19a,b). Sintetizirani spojevi testirani su na antimikrobno i
antitumorsko djelovanje. Ispitivanje antimikrobnog djelovanja provedeno je s koncen-
tracijama otopina 0,88, 0,44 i 0,22 mg mm–2 i uspore|eno s referentnim lijekovima cefo-
taksimom i piperacilinom. Rezultati pokazuju da su 3-(1-supstituirani indol-3-il)kinok-
salin-2(1H)oni (11a,b) i 2-(4-metil piperazin-1-il)-3-(1-supstituirani indol-3-il) kinoksalini
(15a,b) najaktivniji spojevi na sojeve P. aeruginosa, B. cereus i S. aureus, dok su 2-klor-3-(1-
-supstituirani indol-3-il)kinoksalini (12a,b) najaktivniji na C. albicans (usporedba s nista-
tinom). Osim toga, 2-klor-3-(1-benzil indol-3-il) kinoksalin (12a) pokazuje veliku u~in-
kovitost na tumore ovarija mi{eva (supresija rast a tumora 100 ± 0,3 %).
Klju~ne rije~i: 2-klor-3-(1-benzil)kinoksalini, 2-klor-3-(1-benzoilindol-3-il)kinoksalini, antimikrobno
djelovanje, antitumorsko djelovanje
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